- Home
- MRK
MRK
Merck & Company Inc. (new)
as 02-21-2025 4:00pm EST
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | KENILWORTH |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $120.31 | AVG Volume (30 days): | 18.6M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 6.74 | EPS Growth: | 4711.66 |
| 52 Week Low/High: | $81.04 - $134.63 | Next Earning Date: | 02-04-2025 |
| Revenue: | $64,168,000,000 | Revenue Growth: | 6.74% |
| Revenue Growth (this year): | 2.57% | Revenue Growth (next year): | 6.21% |
Stock Insider Trading Activity of Merck & Company Inc. (new) (MRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Downing Cristal N | MRK | Chief Comm. & Public Afrs Ofcr | Feb 6 '25 | Sell | $88.76 | 2,361 | $209,550.79 | 7,085 |
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
StockStory
a day ago
2 Healthcare Stocks with Big Upside and 1 to Skip
MT Newswires
2 days ago
Merck & Co. Insider Sold Shares Worth $714,745, According to a Recent SEC Filing
Insider Monkey
4 days ago
Merck & Co., Inc. (MRK): Among the Cheap High Dividend Stocks to Invest In Now
Insider Monkey
4 days ago
Is Merck & Co., Inc. (MRK) the Best Very Cheap Stock To Buy Right Now?
Benzinga
4 days ago
Europe Approves Merck's Cancer Drug For Two Indications
Insider Monkey
4 days ago
Merck & Co., Inc. (MRK): Among the Best Drug Stocks to Buy Now
Business Wire
4 days ago
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
Insider Monkey
6 days ago
Is Merck & Co., Inc. (MRK) the Most Oversold S&P 500 Stock in 2024?
Compare MRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.